These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15516459)

  • 1. Difficult bacteria, antibiotic resistance and transmissibility in cystic fibrosis.
    Elborn JS
    Thorax; 2004 Nov; 59(11):914-5. PubMed ID: 15516459
    [No Abstract]   [Full Text] [Related]  

  • 2. Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals?
    Jones AM
    Thorax; 2011 Jul; 66(7):558-9. PubMed ID: 21415245
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibiotic-related renal failure and cystic fibrosis.
    Kennedy SE; Henry RL; Rosenberg AR
    J Paediatr Child Health; 2005 Jul; 41(7):382-3. PubMed ID: 16014148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Infections caused by multiresistant bacteria].
    Zahar JR; Ferroni A
    Rev Prat; 2006 Sep; 56(13):1397-404. PubMed ID: 17002063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.
    Waters V; Ratjen F
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):807-19. PubMed ID: 17140357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis.
    Ferroni A; Guillemot D; Moumile K; Bernede C; Le Bourgeois M; Waernessyckle S; Descamps P; Sermet-Gaudelus I; Lenoir G; Berche P; Taddei F
    Pediatr Pulmonol; 2009 Aug; 44(8):820-5. PubMed ID: 19598278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The era of the classical bacterial epidemics is over. Today the challenge is from the "Domestic Germs"].
    Heesemann J
    MMW Fortschr Med; 2005 Jan; 147(4):27-8. PubMed ID: 15745337
    [No Abstract]   [Full Text] [Related]  

  • 8. Longitudinal analysis of FEV1 changes related to antibiotic therapy in children with cystic fibrosis.
    Javadpour S; Jones A; Brownlee K
    Ir Med J; 2007; 100(7):529-32. PubMed ID: 17886526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
    Van Devanter DR
    Respiration; 2007; 74(3):356; author reply 357. PubMed ID: 17204830
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis.
    Valenza G; Tappe D; Turnwald D; Frosch M; König C; Hebestreit H; Abele-Horn M
    J Cyst Fibros; 2008 Mar; 7(2):123-7. PubMed ID: 17693140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bacterial infections of the lungs in mucoviscidosis patients].
    Hogardt M; Heesemann J
    MMW Fortschr Med; 2005 Jan; 147(4):38-40. PubMed ID: 15745340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosfomycin--investigation of a possible new route of administration of an old drug. A case study.
    Cree M; Stacey S; Graham N; Wainwright C
    J Cyst Fibros; 2007 May; 6(3):244-6. PubMed ID: 17055346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological investigation and glycotyping of clinical Pseudomonas aeruginosa isolates from patients with cystic fibrosis by mass spectrometry: association with multiple drug resistance.
    Altman E; Wang Z; Aaron SD; Liu X; Vandemheen KL; Ferris W; Giesbrecht T; Li J
    J Microbiol Methods; 2009 Feb; 76(2):204-8. PubMed ID: 19000720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Isolated pathogen microorganisms in respiratory samples from children with cystic fibrosis].
    Anzaudo MM; Busquets NP; Ronchi S; Mayoral C
    Rev Argent Microbiol; 2005; 37(3):129-34. PubMed ID: 16323660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
    Zhou J; Chen Y; Tabibi S; Alba L; Garber E; Saiman L
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1085-8. PubMed ID: 17158942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on treatment of pulmonary exacerbations in cystic fibrosis.
    Smyth A
    Curr Opin Pulm Med; 2006 Nov; 12(6):440-4. PubMed ID: 17053495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis.
    Rogers GB; Carroll MP; Serisier DJ; Hockey PM; Jones G; Kehagia V; Connett GJ; Bruce KD
    J Clin Microbiol; 2006 Jul; 44(7):2601-4. PubMed ID: 16825392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.
    Beckmann C; Brittnacher M; Ernst R; Mayer-Hamblett N; Miller SI; Burns JL
    Infect Immun; 2005 Jan; 73(1):444-52. PubMed ID: 15618183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.
    Aaron SD
    Paediatr Respir Rev; 2007 Sep; 8(3):256-61. PubMed ID: 17868924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.